Previous researches have shown that HMGB1 inhibitor BoxA reversed lethality of established sepsis, decreased sepsis-induced organ injury, prevented HMGB-induced leukocyte recruit, diminished CTL-induced liver disease in HBV transgenic mice (58–61). This evidence concerns the gene HMGB1 and Sepsis.